for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

164.86USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

134.83

 - 

179.91

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
164.86
Open
--
Volume
--
3M AVG Volume
125.66
Today's High
--
Today's Low
--
52 Week High
179.91
52 Week Low
134.83
Shares Out (MIL)
2,632.48
Market Cap (MIL)
431,542.80
Forward P/E
16.96
Dividend (Yield %)
2.58

Next Event

Johnson & Johnson at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

更多

U.S. CDC Says 212,564,346 Individuals Have Received At Least One Dose Of Covid-19 Vaccine As Of Sept 23

U.S. CDC Says 182,387,840 Individuals Have Been Fully Vaccinated Against Covid-19 As Of Sept 22

EMA Publishes Updated Product Information For Janssen With Increase In Approved Shelf Life

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.

Industry

Biotechnology & Drugs

Contact Info

One Johnson & Johnson Plz

NEW BRUNSWICK, NJ

08933

United States

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.05 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

81.6K

2019

82.1K

2020

82.6K

2021(E)

94.4K
EPS (USD)

2018

8.180

2019

8.680

2020

8.030

2021(E)

9.664
Price To Earnings (TTM)
24.65
Price To Sales (TTM)
4.84
Price To Book (MRQ)
6.20
Price To Cash Flow (TTM)
17.09
Total Debt To Equity (MRQ)
48.12
LT Debt To Equity (MRQ)
43.56
Return on Investment (TTM)
13.70
Return on Equity (TTM)
10.61

Latest News

Latest News

FACTBOX-Vaccines delivered under COVAX sharing scheme for poorer countries

The COVAX facility, backed by the World Health Organization and the Global Alliance for Vaccines and Immunization (GAVI), has delivered over 286 million COVID-19 vaccine doses to 141 countries, GAVI data shows, but in September the organisations running the facility had...

India set to get first J&J COVID vaccine doses in October, says source

India expects to get its first Johnson & Johnson COVID-19 vaccine doses from next month, filled and finished in India by a partner of the U.S. drugmaker, a source with knowledge of the matter told Reuters on Monday.

UPDATE 1-Key data on U.S. J&J, Moderna COVID-19 boosters weeks away, Fauci says

Data needed to determine the advisability of booster shots of the Moderna Inc and Johnson & Johnson COVID-19 vaccines is just weeks away, President Joe Biden's chief medical adviser, Dr. Anthony Fauci, said on Sunday.

UPDATE 1-J&J reports promising Ebola vaccine data

Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.

Indonesia approves J&J, Cansino COVID-19 vaccines for emergency use

Indonesia has approved the single-dose COVID-19 vaccines produced by Janssen Pharmaceutical Companies, part of Johnson & Johnson, and China's CanSino Biological Inc for emergency use, the country's food and drug agency said in a statement on Tuesday. (Reporting by Stanley...

UPDATE 2-Drug companies say enough U.S. states join $26 bln opioid settlement to proceed

Three large U.S. drug distributors and drugmaker Johnson & Johnson will proceed with a proposed $26 billion settlement resolving claims that they fueled the opioid epidemic after "enough" states joined in, the companies said on Saturday.

CORRECTED-Drug companies say enough U.S. states join $26 bln opioid settlement to proceed

Three large U.S. drug distributors and the drugmaker Johnson & Johnson will move forward with a proposed $26 billion settlement resolving claims that they fueled the opioid epidemic after "enough" states joined the deal, according to letters on Saturday reviewed by Reuters...

UPDATE 2-S.Africa's Aspen seeks licence for J&J COVID shot as EU shipments halted

* Shipments of some Aspen-made shots had gone to Europe (Adds J&J comment)

Aspen eyes Serum Institute model as it seeks licence to make J&J vaccine

South Africa's Aspen Pharmacare wants to model itself on India's Serum Institute by getting a licence to manufacture Johnson & Johnson's (J&J) COVID-19 vaccine, Aspen Chief Executive Stephen Saad said on Thursday.

Aspen in talks with J&J to produce and market COVID-19 vaccine

South Africa's Aspen Pharmacare is in talks with Johnson & Johnson over a licence to manufacture, market and sell COVID-19 vaccines in South Africa, according to a company presentation uploaded on its website on Thursday morning.

S.Africa's Aspen and J&J in talks to produce COVID vaccine

South Africa's Aspen Pharmacare is in talks with Johnson & Johnson to produce the finished drug ingredient for manufacturing COVID-19 vaccine, according to a presentation uploaded on the company's website on Thursday.

UPDATE 2-J&J's HIV vaccine fails trial in latest blow to the field

Johnson & Johnson's experimental vaccine failed to provide sufficient protection against HIV to young women in sub-Saharan Africa, in the latest setback to the field after a string of earlier failures.

Johnson & Johnson's HIV vaccine fails mid-stage study in Africa

Johnson & Johnson said on Tuesday its experimental vaccine failed to provide enough protection against HIV in sub-Saharan Africa to young women who are at high risk of being infected.

UPDATE 3-U.S. judge declines to stop J&J from splitting talc liabilities from main business

A U.S. judge declined to stop Johnson & Johnson from taking steps to offload widespread Baby Powder liabilities from the rest of its business, preserving the option for the healthcare company to move thousands of claims from people who used its talc products to a unit that...

Judge allows Johnson & Johnson to split talc liabilities from main business

A federal judge allowed Johnson & Johnson to split its talc-related liabilities from the rest of its business, a decision that could enable the drugmaker to move thousands of claims into bankruptcy.

UPDATE 1-Six U.S. states do not join $26 bln opioid settlements with distributors, J&J

At least six U.S. states, including Georgia, did not fully sign on to a proposed $26 billion settlement with three drug distributors and Johnson & Johnson , which have been accused of fueling the nation's opioid epidemic, according to the states' attorneys general.

Six U.S. states will not join $26 bln opioid settlements with distributors, J&J

At least six U.S. states, including Georgia, have decided they will not fully sign on to a proposed $26 billion settlement with three drug distributors and Johnson & Johnson, which have been accused of fueling the nation's opioid epidemic, according to the states' attorneys...

UPDATE 1-J&J seeks nod for COVID-19 vaccine trial in Indian adolescents

Johnson & Johnson has sought approval from Indian drug regulators to conduct a study of its COVID-19 vaccine among 12- to 17-year-olds, the company said on Friday.

UPDATE 5-J&J says veteran Duato to replace Gorsky as chief executive

Johnson & Johnson on Thursday appointed Joaquin Duato as chief executive officer to replace veteran Alex Gorsky to steer the healthcare conglomerate through the remainder of the coronavirus pandemic.

J&J names Joaquin Duato as chief executive

Johnson & Johnson said on Thursday its Vice Chairman of Executive Committee Joaquin Duato will become chief executive officer from Jan. 3. Its current CEO Alex Gorsky will serve as executive chairman. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up